Activity of luspatercept and ESAs combination for treatment of anemia in lower-risk myelodysplastic syndromes
Journal Title:
Blood Advances
Original Publication Date:
Jul 2023
Bone Marrow Disease(s):
IMPORTANT: UPDATED Guidance for Patients on COVID-19 including Vaccine Information»
Introduction: Patients with myeloid neoplasms such as
Background: Erythropoiesis-stimulating agents (ESAs) are the standard-of-care treatment for anaemia in most patients with lower-risk
Thank you for attending the 2023 Salt Lake City Patient and Family Conference. We will keep uploading presentations as we receive them, please keep checking back for updates.
Watch this informative patient panel from the 2023 Patient and Family Conference in Salt Lake City, Utah. This session was led by Jill Gahlsford, RN, of Huntsman Cancer Institute.
Ryotaro Nakamura, MD, City Of Hope, explains the reasons why the specialist may recommend a bone marrow transplant for a patient with MDS. The recording includes questions from the audience.
